January 2, 2018

Verseon Corporation (“Verseon” or the “Company”)

Additional Listing and Total Voting Rights

Fremont, Calif.—Verseon, a technology-based pharmaceutical company, announces that application has been made for 24,096 new shares of common stock (“Common Shares”) of par value $0.001 each to be admitted to trading on AIM pursuant to regularly scheduled vesting of restricted stock units (the "Issuance"). The restricted stock units (“RSU”) have been issued to Dr. Thomas Hecht and Dr. Robert Karr, both non-executive Directors of the Company, in relation to the payment of their Director’s fees. Of the 24,096 Common Shares issued, 18,072 Common Shares were issued to Dr. Hecht and 6,024 to Dr. Karr.

Each Director received a stock grant of 36,144 Common Shares for one year of service, as calculated by reference to the closing price of USD 1.66 of the Company’s Common Shares on October 19, 2017. For Dr. Hecht, 18,072 Common Shares have vested on December 31, 2017 and 25% will vest each quarter thereafter, ending on June 30, 2018. For Dr. Karr, 6,024 Common Shares have vested on December 31, 2017 and 25% will vest each quarter thereafter, ending on October 31, 2018.

Following the Issuance, Dr. Hecht will hold 63,400 Common Shares, representing 0.04% of the Company’s issued share capital. Dr. Karr will hold 191,288 Common Shares, representing 0.13% of the Company’s issued share capital.

The 24,096 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on January 5, 2018 ("Admission").

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 151,556,802 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 151,513,885. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.


For further information please contact:

Verseon Corporation
Tina Schlafly +1 (510) 225 9000
Cenkos (NOMAD and Joint Broker)  
Neil McDonald / Beth McKiernan +44 (0) 20 7397 8900
Cantor Fitzgerald Europe (Joint Broker)  
Marc Milmo / Phil Davies / Callum Butterfield +44 (0) 20 7894 7000

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisors)
Henry Harrison-Topham / Jamie Hooper +44 (0) 20 7466 5000

For trade and pharma media enquiries, please contact

Vane Percy & Roberts
Simon Vane Percy +44 (0) 1737 821 890

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen